The decision to prescribe it takes into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism. This announcement comes approximately a year after the Medicines and Healthcare products Regulatory Agency (MHRA) granted a UK licence for E4/DRSP.
Gedeon Richter has announced that its combined oral contraceptive Drovelis® is the first tablet containing estetrol (E4) and drospirenone (DRSP) to be made available on the NHS in England.
RALEIGH, N.C., March 6, 2021 /PRNewswire/ -- Mayne Pharma announced today new data showing treatment with NEXTSTELLIS®,1 a novel, investigational combined oral contraceptive (COC) containing drospirenone (DRSP) and estetrol (E4), resulted in limited changes in endocrine markers, including lower increases in hormone binding globulins, compared with COCs based on ethinyl-estradiol (EE), the synthetic estrogen used in all but one of the marketed COCs. The data was presented at the annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), held virtually in the U.S. from March 5-7.